ClinicalTrials.Veeva

Menu
O

OK Clinical Research | Edmond, OK

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Astegolimab
Atogepant
Ensifentrine
Rocatinlimab
SAR440340
Fluticasone
Symbicort®
SAR443765
Zavegepant
BHV-3500

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 24 total trials

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Enrolling
Asthma
Drug: Placebo
Drug: Rocatinlimab

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Astegolimab
Drug: Placebo

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab (SAR440340)

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Enrolling
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, saf...

Enrolling
Asthma
Drug: Placebo
Drug: Lunsekimig

This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period...

Enrolling
Asthma
Drug: Placebo
Drug: Amlitelimab

The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic m...

Active, not recruiting
Photophobia
Migraine
Drug: Rimegepant

Primary Objective:Primary population (former smokers cohort):* Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of ac...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Sanofi logo
Pfizer logo
Allergan logo
Roche logo
AbbVie logo
Amgen logo
AnaptysBio logo
Avalo Therapeutics logo
Boehringer Ingelheim logo
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems